Leerink Partners Initiates Coverage On MapLight Therapeutics with Outperform Rating, Announces Price Target of $30
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners analyst Marc Goodman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $30.
Leerink Partners analyst Marc Goodman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Outperform rating and announces Price Target of $30.